SS
TCRR

Steve Schonfeld’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Steve Schonfeld’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,600
Closed -$26.6K – 2887
2022
Q4 		$26.6K Sell
26,600
-8,800
-25% -$11.9K ﹤0.01% 2305
2022
Q3 		$64K Sell
35,400
-29,000
-45% -$84.1K ﹤0.01% 2610
2022
Q2 		$187K Sell
64,400
-10,000
-13% -$24.7K ﹤0.01% 1930
2022
Q1 		$205K Buy
74,400
+43,200
+138% +$136K ﹤0.01% 1944
2021
Q4 		$145K Sell
31,200
-210,561
-87% -$1.32M ﹤0.01% 1821
2021
Q3 		$2.06M Buy
+241,761
New +$3.42M 0.02% 702

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Steve Schonfeld's TCRR Position: Q1 2023 in Review

Steve Schonfeld sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 26,600 shares — an estimated $26.6K sold.

Steve Schonfeld first reported a position in TCRR in Q3 2021 and held it in 6 quarters. The position peaked at $2.06M in Q3 2021. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

  • Steve Schonfeld reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Steve Schonfeld sold 26,600 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $26.6K.
  • Steve Schonfeld first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Steve Schonfeld's TCR2 Therapeutics Inc. Common Stock position peaked at $2.06M in Q3 2021.
  • 59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.